Physician profile
David S Haacker
NPI 1902879000
$5,769.03
in general payments reported to CMS, 2019-2025
43 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $577 · 2021: $921 · 2022: $794 · 2023: $916 · 2024: $862 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $880.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $616.34 | 2019-2024 | |
| Amgen INC. | $600.10 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $577.58 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $538.52 | 2020-2025 | Verquvo, Lagevrio, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $395.55 | 2019-2024 | Farxiga, Lokelma, Breztri |
| Amarin Pharma, INC. | $156.64 | 2019-2021 | |
| Exact Sciences Corporation | $145.09 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $135.01 | 2021-2025 | |
| Boston Scientific Corporation | $132.82 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Pfizer INC. | $117.14 | 2021-2024 | |
| Glaxosmithkline, LLC. | $115.51 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $99.67 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $92.66 | 2019-2020 | |
| Atricure, INC. | $84.68 | 2019-2023 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $79.57 | 2022-2025 | Barostim Neo System |
| Baxter Healthcare | $78.41 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $72.79 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $71.87 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $71.09 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $69.79 | 2022-2023 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $65.25 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $53.38 | 2024-2025 | Rexulti |
| Medtronic, INC. | $49.86 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $49.19 | 2024 | Zepbound, Mounjaro |
| Abbott Laboratories | $49.08 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $43.60 | 2020-2021 | |
| Dexcom, INC. | $42.91 | 2021-2024 | Dexcom G6 Transmitter |
| Bridgebio Pharma, INC. | $33.71 | 2025 | Attruby |
| Gilead Sciences, INC. | $28.63 | 2019-2020 | |
| Biogen, INC. | $26.71 | 2021 | |
| Heartflow, INC. | $22.42 | 2024 | |
| Angiodynamics, INC. | $18.96 | 2023 | Angiovac |
| Philips North America LLC | $17.99 | 2022 | |
| Lundbeck LLC | $17.06 | 2024 | Rexulti |
| Abiomed | $17.01 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.42 | 2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2019 | |
| Biocryst US Sales Co., LLC | $14.54 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.42 | 2025 | Onpattro |
| Esperion Therapeutics, INC. | $14.31 | 2021 | |
| Abbvie INC. | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Haacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.